Glanzmann Thrombasthenia 10 Years Later: Progress Made and Future Directions

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Glanzmann thrombasthenia (GT) is the most common inherited platelet disorder (IPD), characterized by mucocutaneous bleeding due to platelet aggregation failure.
• The molecular basis of GT involves insufficient or defective αIIbβ3 integrin, encoded by the ITGA2B and ITGB3 genes, which is crucial for fibrinogen binding and platelet aggregation.

Purpose of the Study:

• To review advancements in diagnosing Glanzmann thrombasthenia using next-generation sequencing (NGS).
• To explore the genetic underpinnings of bleeding variability in inherited platelet disorders.
• To discuss emerging therapeutic strategies for Glanzmann thrombasthenia and other IPDs.

Main Methods:

• Application of next-generation sequencing (NGS) for accelerated genotyping of Glanzmann thrombasthenia (GT).
• Evaluation of variants in hemostasis and vascular genes using NGS to understand bleeding phenotype variability.
• Review of current and future therapeutic interventions for GT and IPDs.

Main Results:

• NGS has significantly improved the speed and accuracy of GT genotyping and mutation curation.
• NGS-based variant evaluation is crucial for understanding inter-patient variability in bleeding.
• Glycoprotein VI emerges as a potential mechanosensitive backup for αIIbβ3 in thrombus formation.

Conclusions:

• Advances in NGS are transforming the diagnosis and understanding of Glanzmann thrombasthenia and inherited platelet disorders.
• National networks and improved diagnostics are enhancing patient care for IPDs.
• Promising future therapies include monoclonal antibodies, gene therapy, and CRISPR/Cas9 technology for severe cases.